Supernus Pharmaceuticals, Inc. (SUPN)
26.12
-0.62
(-2.32%)
USD |
NASDAQ |
Nov 06, 15:30
Supernus Pharmaceuticals Research and Development Expense (Annual) : 104.13M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 104.13M |
| December 31, 2024 | 106.36M |
| December 31, 2023 | 89.12M |
| December 31, 2022 | 71.55M |
| December 31, 2021 | 72.87M |
| December 31, 2020 | 71.66M |
| December 31, 2019 | 69.10M |
| December 31, 2018 | 89.21M |
| December 31, 2017 | 49.58M |
| December 31, 2016 | 42.79M |
| Date | Value |
|---|---|
| December 31, 2015 | 29.14M |
| December 31, 2014 | 19.59M |
| December 31, 2013 | 17.24M |
| December 31, 2012 | 23.52M |
| December 31, 2011 | 30.63M |
| December 31, 2010 | 35.15M |
| December 31, 2009 | 29.26M |
| December 31, 2008 | 30.46M |
| December 31, 2007 | 19.27M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Indivior Pharmaceuticals, Inc. (DELISTED) | 80.00M |
| ANI Pharmaceuticals, Inc. | 51.66M |
| Prestige Consumer Healthcare, Inc. | -- |
| Bristol Myers Squibb Co. | 9.492B |
| Liquidia Corp. | 38.45M |